Nicholas Mitsiades

24.2k total citations · 5 hit papers
172 papers, 15.3k citations indexed

About

Nicholas Mitsiades is a scholar working on Molecular Biology, Oncology and Hematology. According to data from OpenAlex, Nicholas Mitsiades has authored 172 papers receiving a total of 15.3k indexed citations (citations by other indexed papers that have themselves been cited), including 115 papers in Molecular Biology, 54 papers in Oncology and 44 papers in Hematology. Recurrent topics in Nicholas Mitsiades's work include Multiple Myeloma Research and Treatments (40 papers), Cell death mechanisms and regulation (36 papers) and Ubiquitin and proteasome pathways (31 papers). Nicholas Mitsiades is often cited by papers focused on Multiple Myeloma Research and Treatments (40 papers), Cell death mechanisms and regulation (36 papers) and Ubiquitin and proteasome pathways (31 papers). Nicholas Mitsiades collaborates with scholars based in United States, Greece and Germany. Nicholas Mitsiades's co-authors include Constantine S. Mitsiades, Kenneth C. Anderson, Teru Hideshima, Vassiliki Poulaki, Nikhil C. Munshi, Paul G. Richardson, Dharminder Chauhan, Steven P. Treon, Robert Schlossman and Maria Tsokos and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Biological Chemistry and Journal of Clinical Investigation.

In The Last Decade

Nicholas Mitsiades

169 papers receiving 14.9k citations

Hit Papers

NF-κB as a Therapeutic Target in Multiple Myeloma 2002 2026 2010 2018 2002 2002 2003 2005 2002 250 500 750
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. NF-κB as a Therapeutic Target in Multiple Myeloma
    2002 752 citations Teru Hideshima, Dharminder Chauhan et al. profile →
  2. Molecular sequelae of proteasome inhibition in human multiple myeloma cells
    2002 597 citations Nicholas Mitsiades, Vassiliki Poulaki et al. Proceedings of the National Academy of Sciences profile →
  3. The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications
    2003 575 citations Nicholas Mitsiades, Constantine S. Mitsiades et al. Blood profile →
  4. A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib
    2005 560 citations Dharminder Chauhan, Klaus Podar et al. profile →
  5. Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications
    2002 544 citations Nicholas Mitsiades, Constantine S. Mitsiades et al. Blood profile →

Peers

Nicholas Mitsiades
Constantine S. Mitsiades United States
Brett P. Monia United States
Bart Vanhaesebroeck United Kingdom
F Grignani Italy
Paul Dent United States
Steven Grant United States
Victoria M. Richon United States
Saverio Minucci Italy
Elisa de Stanchina United States
Martin McMahon United States
Constantine S. Mitsiades United States
Nicholas Mitsiades
Citations per year, relative to Nicholas Mitsiades Nicholas Mitsiades (= 1×) peers Constantine S. Mitsiades

Countries citing papers authored by Nicholas Mitsiades

Since Specialization
Citations

This map shows the geographic impact of Nicholas Mitsiades's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Nicholas Mitsiades with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Nicholas Mitsiades more than expected).

Fields of papers citing papers by Nicholas Mitsiades

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Nicholas Mitsiades. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Nicholas Mitsiades. The network helps show where Nicholas Mitsiades may publish in the future.

Co-authorship network of co-authors of Nicholas Mitsiades

This figure shows the co-authorship network connecting the top 25 collaborators of Nicholas Mitsiades. A scholar is included among the top collaborators of Nicholas Mitsiades based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Nicholas Mitsiades. Nicholas Mitsiades is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Zhang, Xiong, Yang Yang, Xingling Zheng, et al.. (2025). Effective therapeutic targeting of tumor lineage plasticity in neuroendocrine prostate cancer by BRD4 inhibitors. Acta Pharmaceutica Sinica B. 15(3). 1415–1429. 2 indexed citations
2.
Ning, Shu, Wei Lou, Alan P. Lombard, et al.. (2024). PINK1-Mediated Mitochondrial Activity Confers Olaparib Resistance in Prostate Cancer Cells. Cancer Research Communications. 4(11). 2976–2985.
3.
Wang, Weicang, Jun Yang, Molly M. Gilligan, et al.. (2024). Enhancing cancer immunotherapy via inhibition of soluble epoxide hydrolase. Proceedings of the National Academy of Sciences. 121(7). e2314085121–e2314085121. 12 indexed citations
4.
Ning, Shu, Enming Xing, Wei Lou, et al.. (2024). LX1 Dual Targets AR Variants and AKR1C3 in Advanced Prostate Cancer Therapy. Cancer Research. 84(21). 3617–3628. 4 indexed citations
5.
Dowst, Heidi, Neda Zarrin‐Khameh, Patricia Castro, et al.. (2023). Incidental detection of FGFR3 fusion via liquid biopsy leading to earlier diagnosis of urothelial carcinoma. npj Precision Oncology. 7(1). 123–123. 4 indexed citations
6.
Ittmann, Michael, et al.. (2022). Racial disparities in prostate cancer: A complex interplay between socioeconomic inequities and genomics. Cancer Letters. 531. 71–82. 48 indexed citations
7.
Dhimolea, Eugen, Ricardo De Matos Simoes, Xiang Weng, et al.. (2020). Pleiotropic Mechanisms Drive Endocrine Resistance in the Three-Dimensional Bone Microenvironment. Cancer Research. 81(2). 371–383. 12 indexed citations
8.
Thorek, Daniel L.J., Anson T. Ku, Nicholas Mitsiades, et al.. (2018). Harnessing Androgen Receptor Pathway Activation for Targeted Alpha Particle Radioimmunotherapy of Breast Cancer. Clinical Cancer Research. 25(2). 881–891. 21 indexed citations
9.
Geng, Chuandong, Kimal Rajapakshe, Shrijal S. Shah, et al.. (2014). Androgen Receptor Is the Key Transcriptional Mediator of the Tumor Suppressor SPOP in Prostate Cancer. Cancer Research. 74(19). 5631–5643. 132 indexed citations
10.
Mitsiades, Nicholas, Clifford C. Sung, Nikolaus Schultz, et al.. (2012). Distinct Patterns of Dysregulated Expression of Enzymes Involved in Androgen Synthesis and Metabolism in Metastatic Prostate Cancer Tumors. Cancer Research. 72(23). 6142–6152. 175 indexed citations
11.
Ooi, Melissa, Patrick Hayden, Vassiliki Kotoula, et al.. (2009). Interactions of the Hdm2/p53 and Proteasome Pathways May Enhance the Antitumor Activity of Bortezomib. Clinical Cancer Research. 15(23). 7153–7160. 53 indexed citations
12.
McMillin, Douglas W., Melissa Ooi, Jake Delmore, et al.. (2009). Antimyeloma Activity of the Orally Bioavailable Dual Phosphatidylinositol 3-Kinase/Mammalian Target of Rapamycin Inhibitor NVP-BEZ235. Cancer Research. 69(14). 5835–5842. 105 indexed citations
13.
Kotoula, Vassiliki, Galinos Fanourakis, Triantafyllia Κoletsa, et al.. (2009). Mutational analysis of the BRAF, RAS and EGFR genes in human adrenocortical carcinomas. Endocrine Related Cancer. 16(2). 565–572. 38 indexed citations
14.
Michalakis, Konstantinos, et al.. (2007). Serum Adiponectin Concentrations and Tissue Expression of Adiponectin Receptors Are Reduced in Patients with Prostate Cancer: A Case Control Study. Cancer Epidemiology Biomarkers & Prevention. 16(2). 308–313. 152 indexed citations
15.
Poulaki, Vassiliki, Antonia M. Joussen, Nicholas Mitsiades, et al.. (2004). Insulin-Like Growth Factor-I Plays a Pathogenetic Role in Diabetic Retinopathy. American Journal Of Pathology. 165(2). 457–469. 116 indexed citations
16.
Mitsiades, Constantine S., Nicholas Mitsiades, Andrew L. Kung, Ciaran J. McMullan, & Kenneth C. Anderson. (2004). IGF-II is a major proliferative/anti-apoptotic cytokine and a therapeutic target in multiple myeloma, other hematologic neoplasias and solid tumors.. Cancer Research. 64. 559–560. 1 indexed citations
17.
Tai, YT, Klaus Podar, Reshma Shringarpure, et al.. (2003). Insulin-like growth factor-1 induces adhesion and migration in human multiple myeloma cells via activation of b1-integrin and phosphatidylinositol 3-kinase/AKT signaling beta.. Blood. 102(11). 33 indexed citations
18.
Joussen, Antonia M., Vassiliki Poulaki, Wenying Qin, et al.. (2002). Retinal Vascular Endothelial Growth Factor Induces Intercellular Adhesion Molecule-1 and Endothelial Nitric Oxide Synthase Expression and Initiates Early Diabetic Retinal Leukocyte Adhesion in Vivo. American Journal Of Pathology. 160(2). 501–509. 320 indexed citations
19.
Poulaki, Vassiliki, Constantine S. Mitsiades, Antonia M. Joussen, et al.. (2002). Constitutive Nuclear Factor-κB Activity Is Crucial for Human Retinoblastoma Cell Viability. American Journal Of Pathology. 161(6). 2229–2240. 38 indexed citations
20.
Bornstein, SR, Elizabeth Webster, David J. Torpy, et al.. (1998). Chronic Effects of a Nonpeptide Corticotropin-Releasing Hormone Type I Receptor Antagonist on Pituitary-Adrenal Function, Body Weight, and Metabolic Regulation1. Endocrinology. 139(4). 1546–1555. 90 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Constantine S. Mitsiades Breakdown of academic impact, for papers by Brett P. Monia Breakdown of academic impact, for papers by Bart Vanhaesebroeck Breakdown of academic impact, for papers by F Grignani Breakdown of academic impact, for papers by Paul Dent Breakdown of academic impact, for papers by Steven Grant Breakdown of academic impact, for papers by Victoria M. Richon Breakdown of academic impact, for papers by Saverio Minucci Breakdown of academic impact, for papers by Elisa de Stanchina Breakdown of academic impact, for papers by Martin McMahon
Rankless by CCL
2026